• Citer

Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression

par Wildiers, Hans;Meyskens, Thomas;Marreaud, Sandrine;Dal Lago, Lissandra ;Vuylsteke, Peter;Curigliano, Giuseppe;Waters, Simon;Brouwers, Barbara;Meulemans, B.;Sousa, Berta;Poncet, Coralie;Brain, Etienne
Référence Breast, 64, page (100-111)
Publication Publié, 2022-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression
Auteur:	Wildiers, Hans; Meyskens, Thomas; Marreaud, Sandrine; Dal Lago, Lissandra; Vuylsteke, Peter; Curigliano, Giuseppe; Waters, Simon; Brouwers, Barbara; Meulemans, B.; Sousa, Berta; Poncet, Coralie; Brain, Etienne
Informations sur la publication:	Breast, 64, page (100-111)
Statut de publication:	Publié, 2022-08
Sujet CREF:	Chirurgie
Mots-clés:	Frail patients
	HER2 positive breast cancer
	Metronomic chemotherapy
	Older patients
	Pertuzumab
	T-DM1
	Trastuzumab
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0960-9776
	info:doi/10.1016/j.breast.2022.05.004
	info:pii/S0960977622000960
	info:scp/85131036839
	info:pmid/35636341